Project Description

Ruxolitinib

  • Brief description of the drug and MOA
  • Clinical development program
  • Phase II study update
  • Comfort I & II trials – 2 and 3 year updates + overall survival and bone marrow fibrosis results (stabilization, improvement).

Claire Harrison, MD

Consultant Haematologist
Guy’s and St. Thomas’, NHS Foundation Trust. London, UK

Back to sessions
Next session